Skip to main content

Testosterone Therapy for Transgender Patients May Be Safer Than Thought

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 28, 2023.

By Ernie Mundell HealthDay Reporter

TUESDAY, Nov. 28, 2023 -- Transgender people transitioning to male (transmasculine) identity typically take testosterone therapy as part of the process.

There have been worries that the treatment might spur erythrocytosis, an abnormally high concentration of red blood cells in blood that could prove dangerous.

But new research should help allay those fears: The largest study on the subject to date finds no significant risk.

“Providers should feel more comfortable prescribing testosterone when it is indicated. Patients and the families of patients should feel reassured regarding at least this one source of anxiety about treatment," said study senior author Dr. Joshua Safer. He's executive director of the Mount Sinai Center for Transgender Medicine and Surgery in New York City.

The new research was published Nov. 27 in The Journal of Clinical Endocrinology and Metabolism.

The study involved nearly 6,700 transmasculine patients being treated with injectable testosterone across the United States. Safer's team tracked hematocrit, a standard test measuring levels of red blood cells, and compared those results to each patient's blood levels of testosterone.

The result: People on testosterone therapy did have slightly higher hematocrit, the team found, but it never reached levels likely to be clinically significant.

Less than 1% of the transmasculine people tested had a hematocrit exceeding 54% -- the level at which doctors recommend patients receive treatment for erythrocytosis.

Those numbers are smaller than results from other studies, Safer's group noted.

"These results should help providers feel more comfortable prescribing testosterone as part of GAHT [gender-affirming hormone therapy],” the study first author, Nithya Krishnamurthy, a second-year medical student at Icahn Mount Sinai, said in a Mount Sinai news release.

Safer agreed.

“A major concern of patients, providers, and parents is the safety of hormone therapy for transgender and gender-diverse people," he said in the news release. "The findings from this study represent very important reassurance regarding the safety of testosterone as masculinizing treatment."

Sources

  • Mount Sinai Health System, news release, Nov. 27, 2023

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Current Screening Might Miss Prostate Cancer in Transgender Women

MONDAY, July 1, 2024 -- Current screening standards could miss early-stage prostate cancer in transgender women, a new study warns. Prostate cancer tests look for...

U.S. Supreme Court Agrees to Hear Case on Medical Care for Transgender Youth

MONDAY, June 24, 2024 -- The U.S. Supreme Court announced Monday that it would hear a case on a Tennessee law that bans transgender minors from receiving certain medical...

Rates of Distress, Depression Have Doubled Among Transgender Americans Since 2014

MONDAY, June 24, 2024 -- The rate of self-reported mental distress and depression among American adults who identify as transgender or gender-diverse (TGD) has more than doubled...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.